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mean (SD) age of 55.3 (5.5) years and received pravastatin (40mg/day). The placebo group had a mean (SD) age of 55.1 (5.5) years.
Study design
The study was a double-blind, randomized, placebo controlled trial, carried out in three health board districts. The mean duration of the follow-up was 4.9 years. The cumulative rates of loss to follow up at the end of 5 year follow-up were 30.8% in the placebo group and 29.6% in the pravastatin group (NS). Permuted blocked randomisation was used to stratify patients in terms of centre and time of recruitment. Subjects were evaluated every three months by trial nurses and every year by the trial physicians.
Analysis of effectiveness
The principle used in the analysis of effectiveness was intention to treat. The primary endpoints over the five years of the study were the combined endpoint of CHD death plus non-fatal myocardial infarction, CHD death, and non-fatal myocardial infarction. The number of deaths from non-cardiovascular causes was also reported. Transition rates from health to cardiovascular disease were calculated for each of the following definitions: An exponential regression model was used to estimate the adjusted hazard rates in various subgroups according to various risk profiles for cardiovascular disease. The study groups were found to be well balanced in terms of baseline characteristics.
Effectiveness results
The use of the intervention drug was associated with a reduction of 31% (95% CI: 17% -43%, p<0.001) in the combined endpoint of death from CHD or non-fatal MI (248 cases in the placebo group versus 174 in the intervention group). Relative risk reduction for nonfatal MI alone was 31% (15% -45%, p<0.001; 204 cases in the placebo group versus 143 in the intervention) and for death from CHD alone was 28% (-10% -52%, p=0.13; 52 cases and 38 cases). The number of deaths from non-cardiovascular causes was 62 in the placebo group versus 56 in the intervention group (p=0.54) with a risk reduction of 11% (-28% -38%).
The transition rates for the cohort of patients receiving pravastatin in terms of hazards/1000 person years were as follows:
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Clinical conclusions
Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from non-cardiovascular causes in men with moderate hypercholesterolaemia and no history of myocardial infarction.
Modelling
The transition rates (hazards) over the five years of the trial and the proportion of transitions due to each type of event, plus the cost of transition, were estimated in the framework of an economic model.
Measure of benefits used in the economic analysis
The measures of benefits were life years gained and number needed to treat (NNT) to prevent transition. These were based on the difference between the age and sex specific cumulative curve for Scotland (data from a report published in 1994) and the event specific curves (from a study addressing the Scottish record linkage system on comparable cardiovascular events in Scotland between 1981 and 1994), with the simplifying assumption of risk factors for cardiovascular disease having no other effects on life expectancy.
